{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:50:53Z","timestamp":1791478253035,"version":"4.3.4"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2020,4,8]],"date-time":"2020-04-08T00:00:00Z","timestamp":1586304000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2020,4,8]],"date-time":"2020-04-08T00:00:00Z","timestamp":1586304000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Hepatology"],"published-print":{"date-parts":[[2020,7]]},"abstract":"<jats:sec>\n            <jats:title>Background and Aims<\/jats:title>\n            <jats:p>Among treatment\u2010naive individuals with chronic hepatitis C viral (HCV) infection and without cirrhosis, glecaprevir\/pibrentasvir for 8 weeks is recommended. The aim of this analysis was to evaluate the efficacy of glecaprevir\/pibrentasvir for 6 weeks in people with acute and recent HCV infection.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Approach and Results<\/jats:title>\n            <jats:p>In this open\u2010label, single\u2010arm, multicenter, international pilot study, adults with recent HCV (duration of infection &lt; 12 months) received glecaprevir\/pibrentasvir 300\/120 mg daily for 6 weeks. Primary infection was defined by first positive anti\u2010HCV antibody and\/or HCV RNA within 6 months of enrollment and either acute clinical hepatitis within the past 12 months (symptomatic seroconversion illness or alanine aminotransferase &gt; 10\u00a0\u00d7\u00a0upper limit of normal) or anti\u2010HCV antibody seroconversion within 18 months. Reinfection was defined as new positive HCV RNA within 6 months of enrollment and evidence of prior spontaneous or treatment\u2010induced clearance. The primary endpoint was sustained virologic response at 12 weeks posttreatment (SVR12). Thirty men (median age 43 years, 90% men who have sex with men) received treatment, of whom 77% (n\u00a0=\u00a023) were human immunodeficiency virus\u2013positive, 47% (n\u00a0=\u00a014) had ever injected drugs, and 13% (n\u00a0=\u00a04) had HCV reinfection. The majority had HCV genotype 1 (83%, n\u00a0=\u00a025), followed by genotype 4 (10%, n\u00a0=\u00a03) and genotype 3 (7%, n\u00a0=\u00a02). At baseline, median estimated duration of infection was 29 weeks (range 13, 52) and median HCV RNA was 6.2 log<jats:sub>10<\/jats:sub> IU\/mL (range 0.9, 7.7). SVR12 in the intention\u2010to\u2010treat and per\u2010protocol populations was achieved in 90% (27\/30) and 96% (27\/28), respectively. There was one case of relapse, and there were two cases of nonvirological failure (death, n\u00a0=\u00a01; loss to follow\u2010up, n\u00a0=\u00a01). No treatment\u2010related serious adverse events were seen.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Glecaprevir\/pibrentasvir for 6 weeks was highly effective among people with acute and recent HCV infection, supporting further evaluation of shortened\u2010duration pan\u2010genotypic therapy in this setting.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1002\/hep.31003","type":"journal-article","created":{"date-parts":[[2019,10,24]],"date-time":"2019-10-24T20:49:14Z","timestamp":1571950154000},"page":"7-18","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":39,"title":["Short\u2010Duration Pan\u2010Genotypic Therapy With Glecaprevir\/Pibrentasvir for 6 Weeks Among People With Recent Hepatitis C Viral Infection"],"prefix":"10.1097","volume":"72","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9444-0186","authenticated-orcid":false,"given":"Marianne","family":"Martinello","sequence":"first","affiliation":[{"name":"Kirby Institute,University of New South Wales Sydney,Sydney,Australia"},{"name":"St. Vincent's Hospital,Sydney,Australia"},{"name":"Department of Infectious Diseases,Blacktown Mt. Druitt Hospital,Sydney,Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chloe","family":"Orkin","sequence":"additional","affiliation":[{"name":"Queen Mary University of London,London,UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham","family":"Cooke","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases,Imperial College NHS Trust,St. Mary's Hospital,London,UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Bhagani","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases\/HIV Medicine,Royal Free Hospital,London,UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Gane","sequence":"additional","affiliation":[{"name":"New Zealand Liver Transplant Unit,Auckland City Hospital,Auckland,New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjababu","family":"Kulasegaram","sequence":"additional","affiliation":[{"name":"Guy's and St. Thomas' Hospital,London,UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Shaw","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases,Royal Adelaide Hospital,Adelaide,Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise","family":"Tu","sequence":"additional","affiliation":[{"name":"Kirby Institute,University of New South Wales Sydney,Sydney,Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy","family":"Petoumenos","sequence":"additional","affiliation":[{"name":"Kirby Institute,University of New South Wales Sydney,Sydney,Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippa","family":"Marks","sequence":"additional","affiliation":[{"name":"Kirby Institute,University of New South Wales Sydney,Sydney,Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Grebely","sequence":"additional","affiliation":[{"name":"Kirby Institute,University of New South Wales Sydney,Sydney,Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory J.","family":"Dore","sequence":"additional","affiliation":[{"name":"Kirby Institute,University of New South Wales Sydney,Sydney,Australia"},{"name":"St. Vincent's Hospital,Sydney,Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Nelson","sequence":"additional","affiliation":[{"name":"Chelsea and Westminster Hospital,London,UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gail V.","family":"Matthews","sequence":"additional","affiliation":[{"name":"Kirby Institute,University of New South Wales Sydney,Sydney,Australia"},{"name":"St. Vincent's Hospital,Sydney,Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,4,8]]},"reference":[{"key":"hep31003-bib-0001-20241017","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S2468-1253(16)30075-9","article-title":"Hepatitis C treatment as prevention: evidence, feasibility, and challenges","volume":"1","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"hep31003-bib-0002-20241017","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/s41575-018-0026-5","article-title":"Management of acute HCV infection in the era of direct\u2010acting antiviral therapy","volume":"15","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"hep31003-bib-0003-20241017","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","article-title":"EASL recommendations on treatment of hepatitis C 2018","volume":"69","year":"2018","journal-title":"J Hepatol"},{"key":"hep31003-bib-0004-20241017","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1093\/cid\/ciy585","article-title":"Hepatitis C guidance 2018 update: AASLD\u2010IDSA recommendations for testing, managing, and treating hepatitis C virus infection","volume":"67","year":"2018","journal-title":"Clin Infect Dis"},{"key":"hep31003-bib-0005-20241017","first-page":"837","article-title":"Should we treat acute hepatitis C?","volume":"67","year":"2018","journal-title":"A decision and cost\u2010effectiveness analysis. Hepatology"},{"key":"hep31003-bib-0006-20241017","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S2468-1253(18)30414-X","article-title":"Treatment of acute hepatitis C genotypes 1 and 4 with 8 weeks of grazoprevir plus elbasvir (DAHHS2): an open\u2010label, multicentre, single\u2010arm, phase 3b trial","volume":"4","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"hep31003-bib-0007-20241017","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/j.jhep.2012.07.007","article-title":"Case definitions for acute hepatitis C virus infection: a systematic review","volume":"57","year":"2012","journal-title":"J Hepatol"},{"key":"hep31003-bib-0008-20241017","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/QAD.0b013e328343443b","article-title":"Acute hepatitis C in HIV\u2010infected individuals: recommendations from the European AIDS Treatment Network (NEAT) consensus conference","volume":"25","year":"2011","journal-title":"AIDS"},{"key":"hep31003-bib-0009-20241017","article-title":"The influence of hepatitis C virus genetic region on phylogenetic clustering analysis","volume":"10","year":"2015","journal-title":"PLoS One"},{"key":"hep31003-bib-0010-20241017","doi-asserted-by":"crossref","first-page":"555","DOI":"10.3109\/23744235.2015.1028097","article-title":"Prevalence of polymorphisms with significant resistance to NS5A inhibitors in treatment\u2010naive patients with hepatitis C virus genotypes 1a and 3a in Sweden","volume":"47","year":"2015","journal-title":"Infect Dis (Lond)"},{"key":"hep31003-bib-0011-20241017","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1128\/JCM.06689-11","article-title":"Automating HIV drug resistance genotyping with RECall, a freely accessible sequence analysis tool","volume":"50","year":"2012","journal-title":"J Clin Microbiol"},{"key":"hep31003-bib-0012-20241017","article-title":"Geno2pheno[HCV]\u2014a web\u2010based interpretation system to support hepatitis C treatment decisions in the era of direct\u2010acting antiviral agents","volume":"11","year":"2016","journal-title":"PLoS One"},{"key":"hep31003-bib-0013-20241017","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S1473-3099(16)30408-X","article-title":"Ledipasvir plus sofosbuvir fixed\u2010dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV): an open\u2010label, single\u2010arm, phase 2 study","volume":"17","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"hep31003-bib-0014-20241017","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/jvh.12917","article-title":"Shortened therapy of eight weeks with paritaprevir\/ritonavir\/ombitasvir and dasabuvir is highly effective in people with recent HCV genotype 1 infection","volume":"25","year":"2018","journal-title":"J Viral Hepat"},{"key":"hep31003-bib-0015-20241017","first-page":"113A","article-title":"100% SVR with 8 weeks of ledipasvir\/sofosbuvir in HIV\u2010infected men with acute HCV infection: results from the SWIFT\u2010C Trial [Abstract]","volume":"66","year":"2017","journal-title":"Hepatology"},{"key":"hep31003-bib-0016-20241017","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S2468-1253(17)30003-1","article-title":"Ledipasvir\u2013sofosbuvir for 6 weeks to treat acute hepatitis C virus genotype 1 or 4 infection in patients with HIV coinfection: an open\u2010label, single\u2010arm trial","volume":"2","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"hep31003-bib-0017-20241017","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1002\/hep.28844","article-title":"Sofosbuvir and ribavirin for 6 weeks is not effective among people with recent hepatitis C virus infection: the DARE\u2010C II study","volume":"64","year":"2016","journal-title":"Hepatology"},{"key":"hep31003-bib-0018-20241017","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/hep.28877","article-title":"Short\u2010duration treatment with elbasvir\/grazoprevir and sofosbuvir for hepatitis C: a randomized trial","volume":"65","year":"2017","journal-title":"Hepatology"},{"key":"hep31003-bib-0019-20241017","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1016\/j.jhep.2016.02.022","article-title":"HCV kinetic and modeling analyses indicate similar time to cure among sofosbuvir combination regimens with daclatasvir, simeprevir or ledipasvir","volume":"64","year":"2016","journal-title":"J Hepatol"},{"key":"hep31003-bib-0020-20241017","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nrgastro.2015.97","article-title":"Modelling hepatitis C therapy\u2014predicting effects of treatment","volume":"12","year":"2015","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"hep31003-bib-0021-20241017","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1073\/pnas.1203110110","article-title":"Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half\u2010life","volume":"110","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"hep31003-bib-0022-20241017","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1002\/hep.24272","article-title":"Second\u2010phase hepatitis C virus RNA decline during telaprevir\u2010based therapy increases with drug effectiveness: implications for treatment duration","volume":"53","year":"2011","journal-title":"Hepatology"},{"key":"hep31003-bib-0023-20241017","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/jvh.12351","article-title":"The present and future disease burden of hepatitis C virus (HCV) infections with today's treatment paradigm\u2014volume 2","volume":"22","year":"2015","journal-title":"J Viral Hepat"},{"key":"hep31003-bib-0024-20241017","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/jvh.12248","article-title":"The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm","volume":"21","year":"2014","journal-title":"J Viral Hepat"},{"key":"hep31003-bib-0025-20241017","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/jvh.12476","article-title":"The present and future disease burden of hepatitis C virus infections with today's treatment paradigm\u2014volume 3","volume":"22","year":"2015","journal-title":"J Viral Hepat"},{"key":"hep31003-bib-0026-20241017","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2105\/AJPH.2017.304132","article-title":"Increases in acute hepatitis C virus infection related to a growing opioid epidemic and associated injection drug use, United States, 2004 to 2014","volume":"108","year":"2018","journal-title":"Am J Public Health"},{"key":"hep31003-bib-0027-20241017","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1056\/NEJMp1716871","article-title":"Hepatitis C in injection\u2010drug users\u2014a hidden danger of the opioid epidemic","volume":"378","year":"2018","journal-title":"N Engl J Med"},{"key":"hep31003-bib-0029-20241017","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/cid\/ciw075","article-title":"Can hepatitis C virus (HCV) direct\u2010acting antiviral treatment as prevention reverse the HCV epidemic among men who have sex with men in the United Kingdom? Epidemiological and modeling insights","volume":"62","year":"2016","journal-title":"Clin Infect Dis"},{"key":"hep31003-bib-0030-20241017","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1111\/jvh.12919","article-title":"Effectiveness and cost\u2010effectiveness of interventions targeting harm reduction and chronic hepatitis C cascade of care in people who inject drugs; the case of France","volume":"25","year":"2018","journal-title":"J Viral Hepat"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.31003","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hep.31003","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hep.31003","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/10.1002\/hep.31003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T23:19:03Z","timestamp":1729207143000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1002\/hep.31003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,8]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.31003","relation":{},"ISSN":["0270-9139","1527-3350"],"issn-type":[{"value":"0270-9139","type":"print"},{"value":"1527-3350","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,8]]},"assertion":[{"value":"2019-07-12","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-21","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}